Old and new acetylcholinesterase inhibitors for Alzheimer’s disease

Phenserine Efficacy in Alzheimer's Disease

(2017) Bengt Winblad et al.   JOURNAL OF ALZHEIMERS DISEASE

Design, synthesis and evaluation of novel 7-aminoalkyl-substituted flavonoid derivatives with improved cholinesterase inhibitory activities

(2016) Wen Luo et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer’s disease

(2016) Yuxing Li et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aβ1−42Aggregation Inhibitors for Alzheimer's Disease Therapy

(2016) Youssef Dgachi et al.   ChemMedChem

Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease

(2016) Laís Flávia Nunes Lemes et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Novel Cholinesterase Inhibitors Based on O-Aromatic N,N-Disubstituted Carbamates and Thiocarbamates

(2016) Martin Krátký et al.   MOLECULES

Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats —Is there a potential for Alzheimer’s disease treatment?

(2016) Jan Misik et al.   NEUROSCIENCE LETTERS

Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease

(2015) Robert A. Lenz et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment

(2015) Jan Korabecny et al.   MOLECULES

Taxodione and Extracts fromSalvia austriacaRoots as Human Cholinesterase Inhibitors

(2015) Łukasz Kuźma et al.   PHYTOTHERAPY RESEARCH

A PHASE 2 TRIAL OF THE EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT-126 AS AN ADD-ON TREATMENT IN MILD-TO-MODERATE ALZHEIMER'S DEMENTIA

(2014) Laura M. Gault et al.   Alzheimers & Dementia

EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT-126 AS A MONOTHERAPY TREATMENT IN MILD-TO-MODERATE ALZHEIMER'S DEMENTIA: RESULTS OF A PHASE 2B TRIAL

(2014) Ahmed Othman et al.   Alzheimers & Dementia

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

(2014) Richard Grove et al.   Current Alzheimer Research

Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

(2013) Chieh-Hsin Lin et al.   BIOLOGICAL PSYCHIATRY

The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H3 Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation

(2013) Pradeep J. Nathan et al.   Current Alzheimer Research

Huperzine A for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

(2013) Guoyan Yang et al.   PLoS One

Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment

(2012) Orly Weinreb et al.   CURRENT DRUG TARGETS

In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease

(2010) R. Scott Bitner et al.   NEUROPHARMACOLOGY

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

(2008) Rachelle S Doody et al.   LANCET